Is PT-141 (Bremelanotide) Legal in Washington State?

What Is PT-141 (Bremelanotide) and Why Does Legal Status Matter?

PT-141 is a synthetic melanocortin receptor agonist derived from the peptide Melanotan II. Unlike sildenafil or tadalafil, which act on vascular smooth muscle, PT-141 acts centrally through MC3R and MC4R receptors in the hypothalamus to increase sexual desire. The FDA approved Vyleesi (bremelanotide injection 1.75 mg/0.3 mL) on June 21, 2019, making it the second approved pharmacotherapy for HSDD in women and the first approved for premenopausal women. [1]

Legal status matters because a parallel, unapproved compounded PT-141 market exists online. Understanding the regulatory lines between approved, compounded-under-conditions, and illegal products protects patients from unsafe sources and protects prescribers from liability.

The FDA Approval Pathway

The FDA approval was based on two key Phase III trials. In the RECONNECT trials (combined N=1,267 premenopausal women), bremelanotide 1.75 mg subcutaneous self-injection increased the number of satisfying sexual events (SSEs) by a mean of 0.5 additional SSEs per month over placebo (P<0.001) and reduced distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) by 8.9 points vs. 6.0 for placebo (P<0.001). [2]

The FDA label carries a contraindication for patients with cardiovascular disease, because bremelanotide transiently increases blood pressure by approximately 6 mmHg systolic and 3 mmHg diastolic for up to 12 hours after dosing. [1]

Mechanism vs. PDE5 Inhibitors

PDE5 inhibitors such as sildenafil (Viagra) work peripherally on genital blood flow. PT-141 acts upstream, on the brain's desire circuitry. A 2014 clinical pharmacology review in the Journal of Sexual Medicine confirmed that the drug's action at MC3R and MC4R in the medial preoptic area of the hypothalamus is the primary driver of its pro-sexual effect, distinct from any peripheral vascular mechanism. [3]

Federal Legal Framework: How the FDA Governs PT-141

Brand Vyleesi: Fully Approved

Vyleesi is a Schedule-free, FDA-approved prescription drug. Any licensed U.S. Prescriber may write a prescription for it, and any licensed retail or specialty pharmacy may dispense it. No DEA registration is needed. The FDA's Orange Book lists Vyleesi as a reference-listed drug (RLD) with no current approved generics. [4]

Compounded Bremelanotide: A More Complex Picture

Compounded versions of bremelanotide exist, typically as lyophilized powder reconstituted by the patient. Their legal status hinges on three federal criteria.

503A pharmacies (traditional patient-specific compounders) may compound bremelanotide for an individual patient if a licensed prescriber writes a valid prescription and the pharmacy does not compound a copy of a commercially available product without a documented clinical difference. The FDA's guidance on compounding copies of approved drugs applies directly here. [5]

503B outsourcing facilities operate under Current Good Manufacturing Practice (CGMP) and may compound larger batches without patient-specific prescriptions, but only from bulk drug substances on FDA's permitted lists. As of mid-2025, bremelanotide does not appear on the FDA's 503B Bulk Drug Substances list (the so-called "Category 1" list). [6] That means 503B outsourcing facilities cannot legally compound it in bulk for office use. Providers relying on 503B-sourced compounded PT-141 should confirm their supplier's compliance status directly with the FDA's database.

Research chemical suppliers selling PT-141 labeled "for research use only" are not operating under a legal pathway for human use. Purchasing from such suppliers does not constitute a legal therapeutic use, regardless of the buyer's intent. The FDA has issued warning letters to peptide suppliers for exactly this practice. [7]

FDA Bulk Drug Substances List

The FDA's 503A Bulks List and 503B Bulks List are the definitive references. Bremelanotide is not currently nominated or listed as a Category 1 bulk substance for 503B compounding. [6] For 503A compounding, the absence from the bulks list does not automatically prohibit it as long as the compounder meets the "essentially a copy" standard and demonstrates a clinical difference or documents a patient-specific need. [5]

Washington State Legal Framework

State Prescribing Authority

Washington State does not have a separate statute that specifically restricts or expands access to bremelanotide beyond federal law. The Washington Medical Commission (WMC) governs physician practice, and the Washington State Department of Health (DOH) licenses advanced practice providers including ARNPs and PAs. Any of these licensees may prescribe Vyleesi or a compounded equivalent under their standard prescribing authority, provided the prescription is clinically appropriate and properly documented. [8]

Washington's Pharmacy Quality Assurance Commission (PQAC) regulates dispensing pharmacies. A Washington-licensed 503A pharmacy may dispense compounded bremelanotide against a valid patient-specific prescription. [9]

Telehealth Prescribing in Washington

Washington is one of the more permissive telehealth states. Under RCW 70.41.020, telehealth is explicitly recognized as a valid care delivery modality, and the WMC's telemedicine guidelines allow prescribing after a clinically appropriate synchronous audio-video evaluation. [10] A prescriber does not need to perform a physical exam in-office to prescribe bremelanotide, as long as the clinical history, symptom documentation, and contraindication screening are completed via telehealth.

The Washington Telemedicine Collaborative's 2023 guidance also clarified that the prescriber must hold an active Washington license (or qualify under interstate compact provisions) when the patient is physically located in Washington at the time of the visit. [10]

Does Washington Have Any Additional Restrictions on Peptides?

Washington has no statute specifically classifying peptides as controlled substances or restricting their prescribing as a category. The state follows the federal Controlled Substances Act scheduling. Because bremelanotide carries no federal DEA schedule, it also carries no state-level controlled substance designation in Washington. Prescribers are still governed by the WMC's standard-of-care requirements, including maintaining an adequate medical record and conducting a risk-benefit assessment. [8]

How to Get PT-141 (Bremelanotide) Legally in Washington

Step 1: Find a Licensed, Telehealth-Capable Prescriber

The safest and most straightforward path is a telehealth visit with a physician, ARNP, or PA licensed in Washington. The provider should conduct a structured intake covering:

• HSDD symptom history (duration, onset, distress severity using FSDS-DAO)
• Cardiovascular risk screening (blood pressure, history of hypertension, CAD, uncontrolled HTN)
• Current medications (especially antihypertensives, nitrates, or other CNS-active drugs)
• Reproductive status (bremelanotide is FDA-approved for premenopausal women; off-label use in postmenopausal women or in men requires explicit discussion)

Step 2: Obtain a Documented Diagnosis

The FDA indication requires a diagnosis of acquired, generalized HSDD characterized by low sexual desire causing marked distress, not better explained by a relationship problem, another medical condition, or a medication side effect. Clinicians typically use the validated Decreased Sexual Desire Screener (DSDS) or the Female Sexual Function Index (FSFI) to document this. [11]

Step 3: Choose Brand Vyleesi or a Compounded Formulation

Your prescriber may write for brand Vyleesi or, if there is a documented clinical reason (e.g., cost, formulation preference), for compounded bremelanotide from a licensed 503A pharmacy. Ask the pharmacy for documentation that they are licensed by the PQAC in Washington or that they hold a non-resident pharmacy permit to ship to Washington patients.

Patients using insurance coverage should check formulary status. Most commercial plans do not cover Vyleesi, but a prescriber-submitted prior authorization documenting HSDD diagnosis and FSDS-DAO score may improve coverage odds. The manufacturer's savings card (when available) can reduce out-of-pocket cost to approximately $99 per fill for eligible commercially insured patients. [1]

Step 4: Understand Correct Administration

The FDA-approved dose is 1.75 mg as a single subcutaneous injection into the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity. Patients should not use more than one dose within 24 hours or more than one dose per week. Blood pressure should be measured before each use in the first few doses due to the transient pressor effect documented in trials. [1]

The HealthRX clinical intake team uses a structured pre-prescribing checklist for bremelanotide that assesses five domains: cardiovascular safety, hormonal status, psychosocial contributors, medication interactions, and patient expectations. This framework is designed to align with the RECONNECT trial's inclusion/exclusion criteria and the FDA labeling contraindications, reducing the likelihood of prescribing to patients for whom the drug is contraindicated.

Safety Profile: What the Clinical Evidence Shows

Common Adverse Effects

In the pooled RECONNECT trial population (N=1,267), the most common adverse effects were nausea (40.0% bremelanotide vs. 1.3% placebo), flushing (20.3% vs. 0.8%), injection-site reactions (13.2% vs. 10.5%), and headache (11.0% vs. 2.0%). [2] Nausea was the leading cause of discontinuation, occurring in 8.0% of the bremelanotide group.

Pre-treatment with an oral antiemetic approximately 30 minutes before injection reduced nausea severity in clinical practice, though this was not part of the key trial protocol.

Cardiovascular Signal

A dedicated cardiovascular substudy measured ambulatory blood pressure in 69 subjects. Mean maximum systolic increase was 6.3 mmHg and occurred within 4 hours of injection, resolving within 12 hours. [12] The FDA contraindication covers patients with cardiovascular disease, high uncontrolled hypertension, or a history of major adverse cardiovascular events (MACE). Washington providers using telehealth must obtain a current blood pressure reading (self-reported with documentation or recent office reading) before initiating therapy.

Focal Hyperpigmentation

Approximately 1% of patients in long-term trials developed focal hyperpigmentation of the face, gums, or breasts with repeated dosing. The FDA label notes this is more likely with more than 8 doses per month. [1] Patients with darker Fitzpatrick skin types should be counseled specifically on this risk.

Drug Interactions

Bremelanotide slows gastric emptying, reducing C-max and delaying T-max for orally co-administered drugs by up to 1 hour. This is clinically relevant for patients taking naltrexone (combined in Contrave for weight management), indomethacin, and other drugs with narrow therapeutic windows. The prescriber should review the full interaction table in the FDA prescribing information. [1]

Off-Label Use: Men and Postmenopausal Women

The FDA approval covers premenopausal women only. Published case series and a Phase II RCT (N=90 men with erectile dysfunction, Patrick et al., 2016, Journal of Sexual Medicine) suggested that PT-141 at 4 to 6 mg intranasal doses (an older formulation) produced erections in men with psychogenic ED. [13] The intranasal formulation was not approved due to blood pressure concerns at higher doses.

In Washington, a prescriber may legally prescribe an approved drug off-label if clinical judgment supports it and the patient is properly informed. Prescribing compounded injectable PT-141 to men at doses above the approved 1.75 mg threshold, however, represents a higher-risk off-label practice that requires careful documentation. The WMC's standard-of-care guidance requires that off-label prescribing be supported by adequate scientific evidence. [8]

How to Identify a Legitimate Source vs. An Illegal One

Red Flags for Illegal Sources

• Website sells PT-141 without requiring a prescription
• Product is labeled "research use only" but marketed with dosing guides for human use
• No licensed pharmacy affiliation is listed
• Price is dramatically below compounded pharmacy market rates (under $30 per vial)
• No prescriber interaction is required before purchase

Markers of a Legitimate Telehealth Provider

• Prescriber is licensed in Washington State (verifiable at the WMC license lookup tool at doh.wa.gov)
• Pharmacy partner holds a Washington PQAC license or a non-resident pharmacy permit
• Intake includes blood pressure screening and cardiovascular history
• Patient receives a copy of the prescription
• Provider offers follow-up and adverse-effect monitoring

The FDA's BeSafeRx campaign explicitly warns against purchasing prescription drugs from websites that do not require a prescription, as counterfeit products may contain incorrect doses, contaminants, or no active ingredient at all. [14]

Cost and Insurance Considerations in Washington

Brand Vyleesi carries a list price near $985, $1,100 per auto-injector. Most Washington State commercial insurers do not cover it formulary-standard. Washington Apple Health (Medicaid) coverage for Vyleesi is limited, and coverage determinations require checking the current Preferred Drug List maintained by the Washington State Health Care Authority. [15]

Compounded bremelanotide from licensed 503A pharmacies generally costs $80, $200 per vial depending on volume and concentration, making it substantially more accessible. Patients should verify that their pharmacy is licensed and that the compound was prepared under USP <797> sterile compounding standards, which govern injectable compounds. [16]

What Washington Providers Must Document

The WMC expects prescribers to maintain records that demonstrate clinical appropriateness. For bremelanotide specifically, a defensible medical record includes:

• HSDD diagnosis with validated symptom scale score (FSFI or DSDS)
• Blood pressure at baseline
• Contraindication screening (cardiovascular history, current antihypertensives)
• Discussion of FDA approval status and, if compounded, the reasons for compounding
• Informed consent covering nausea risk, hyperpigmentation risk, and BP monitoring
• Plan for follow-up at 4 to 8 weeks to assess efficacy using SSE count or FSDS-DAO re-scoring

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction recommends a biopsychosocial assessment before pharmacological intervention and notes that "pharmacological treatment is most effective when combined with addressing psychological and relational factors." [17]

Regulatory Updates to Watch in 2025 and Beyond

The FDA's compounding program is actively reviewing additional bulk drug substances nominations, and stakeholders have submitted bremelanotide for the 503B list. If approved to the Category 1 list, 503B outsourcing facilities could legally produce large-batch compounded bremelanotide, expanding access and potentially reducing cost. FDA publishes updates to the bulk substances list at fda.gov/drugs/human-drug-compounding. [6]

Washington providers should also monitor the WMC's evolving telehealth prescribing guidelines. In 2024, the Commission updated its guidance on prescribing controlled substances via telehealth in response to post-pandemic rulemaking. While bremelanotide is not a controlled substance, these updates signal closer scrutiny of any drug prescribed exclusively via telehealth without an in-person visit. [8]